Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
|
Product:
Active Ingredients:
Dosage Form:
New Zealand Sponsor:
Manufacturer:
|
Cardioplegia Solution A
Calcium chloride 0.176g/L
Magnesium chloride 3.25g/L
Potassium chloride 1.19g/L
Sodium chloride 6.43g/L
Solution
Baxter Healthcare Limited
Baxter Healthcare Pty Limited, Sydney, Australia
|
|
Product:
Active Ingredient:
Dosage Form:
New Zealand Sponsor:
Manufacturer:
|
Levomepromazine Hydrochloride
Levomepromazine hydrochloride 25mg/mL
Solution for injection
Max Health Limited
CP Pharmaceuticals Limited, Wrexham, United Kingdom
|
|
Product:
Active Ingredient:
Dosage Form:
New Zealand Sponsor:
Manufacturer:
|
Sodium Valproate 100mg/mL Solution for Injection or Infusion
Sodium valproate 100mg/mL
Solution for injection
Max Health Limited
CP Pharmaceuticals Limited, Wrexham, United Kingdom
|
|
Product:
Active Ingredient:
Dosage Form:
New Zealand Sponsor:
Manufacturer:
|
Zoledronic Acid
Zoledronic acid monohydrate 0.8528mg/mL
equivalent to zoledronic acid 0.8mg/mL
Concentrate for infusion
Max Health Limited
Hameln Pharmaceuticals GmbH, Hameln, Germany
|
Dated this 1st day of April 2016.
CHRIS JAMES, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).
Gazette.govt.nz